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Introduction: CXCL14 was a significantly under-expressed mRNA in hepatocellular car-
cinoma tissues according to our microarray analysis, as well as head and neck squamous cell
carcinoma and cervical squamous cell carcinoma. CXCL14 was considered a tumor sup-
pressor in some studies; however, its role in HBV infection has not been identified.
Methods: CXCL14 mRNA expression was quantified from 20 male HCC patients, and the
fold change in cancer tissues was calculated by comparisons with normal adjacent tissues.
Overall, 212 patients with chronic HBV infection and 180 HBV-free controls were recruited
to investigate the association between CXCL14 polymorphisms and HBV progression as
well as liver function parameters. Serum CXCL14 levels were determined by enzyme-linked
immunosorbent assay (ELISA), and comparisons were made between different HBV status
and different CXCL14 genotypes.
Results: The mRNA expression of CXCL14 was 0.33-fold in HCC tissues when compared
with adjacent tissues. The frequencies of rs2237062 and rs2547, but not rs2237061, were
significantly different between patients with mild hepatitis and moderate-to-severe hepatitis.
Moreover, rs2237062 and rs2547 polymorphisms correlated with impaired liver function
parameters. ELISA results suggested that HBV-free controls had the highest level of
CXCL14, while mild hepatitis patients had low levels, and patients with moderate-to-
severe hepatitis had the lowest level. GA+AA genotypes of rs2547 were associated with
reduced levels of serum CXCL14 because it introduced a stop codon at residue 109.
Conclusion: CXCL14 was significantly suppressed in HBV-related HCC tissues, and its
polymorphisms were linked with advanced stage chronic HBV infection and impaired liver
function.
Keywords: CXCL14, HBV infection, disease progression, polymorphism
Introduction
According to the latest statistics published by Bray et al,1 liver cancer qualifies as
the sixth most common cancer globally, while its mortality ranked fourth for all
types of cancers, and it is estimated that about 841,000 newly diagnosed cancer
cases and 782,000 deaths occur annually worldwide. Its incidence also varies
markedly in different regions; in particular, liver cancer has a high incidence in
Eastern Asia, South-Eastern Asia, and Northern Africa. Hepatocellular carcinoma
(HCC) is the most common type of liver cancer, comprising 70%–85% of all
diagnosed liver cancer cases, and intrahepatic cholangiocarcinoma along with
other rare types can be found in 10%–15% of total cases.2 It has been generally
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acknowledged that hepatitis B virus (HBV) and hepatitis
C virus infection are the major risk factors for developing
HCC, and a systematic review revealed that a high propor-
tion of HBV infection is found in HCC cases originating
from Eastern Asia, especially China, where approximately
76% of HCC cases were HBV positive.3 The Chinese
Center for Disease Control and Prevention conducted
a national-wide serological survey in 2014 involving
31,713 study participants aged from 1 to 29 years, and
revealed a significant reduction of HBV surface antigen
prevalence in samples compared with a prevalence of 10%
in 1992.4 Such a significant reduction of HBV surface
antigen prevalence can be attributed to the implementation
of the Expanded Program on Immunization, offering HBV
vaccination to every child after birth. Despite the rapid
progress made in reducing HBV prevalence, especially in
the young generation, its prevalence remains high in peo-
ple aged above 50 years old because of the lack of
a therapy that eradicates chronic HBV infection.5 China
has the largest population in the world; therefore, large
amounts of people with chronic HBV infection are at risk
of developing HCC. However, among the large amount of
chronic HBV patients, only a few eventually progress to
HCC, indicating that other factors, including genetic fac-
tors, are involved in the development of HCC.
In our previous study, we used microarray analysis to
investigate the genome-wide long non-coding RNA and
mRNA expression profile of HCC tissues and adjacent
normal tissues collected from male HBV-related HCC
cases.6 The results indicated that chemokine ligand 14
(CXCL14) was the most under-expressed mRNA in HCC
tissues with a fold change of 58.03, when compared with
adjacent normal tissues. A previous study showed that
CXCL14 expression was downregulated in HCC tissues,
and an in vitro assay showed it induced tumor cell
apoptosis.7 As a member of the CXC chemokine family,
it was first identified in breast and kidney cells and was
shown to be constitutively and widely expressed in normal
tissues.8 An in situ mRNA hybridization study suggested
that the expression of CXCL14 mRNAwas absent in head
and neck squamous cell carcinoma and cervical squamous
cell carcinoma.9 However, publications have emerged that
offer contradictory findings regarding CXCL14 expression
in cancer. For example, its high expression in stroma was
correlated with a shorter survival of breast cancer.10 To
date, there has been little published data on CXCL14
expression in HCC. A genome-wide association study
conducted in the Japanese population suggested that an
intron polymorphism rs2237062 was associated with the
elevated risk of HCC in patients with chronic HCV
infection.11 We conducted the present study to confirm
the expression of CXCL14 in HCC and to investigate its
role in the progression of chronic HBV infection, which is
an intermediate stage in the development of HCC.
Materials and Methods
HBV-Related HCC Subjects
During the study period ofNovember 2015 toDecember 2017,
20 male HCC patients with chronic HBV infection were
included from Zhongshan Hospital, Xiamen University. The
inclusion criteriawere as follows: (1) pathologically diagnosed
with primaryHCC (ICD10:C22.9); (2)male; (3) chronicHBV
infection confirmed by ELISA prior to the onset of HCC; and
(4) permanent residentswho lived inXiamenover 10 years and
aging from 20 to 79 years. Patients were excluded if any of the
following conditions were met: (1) presence of cancers other
than HCC; (2) autoimmune hepatitis or toxic hepatitis; and (3)
refusal to participate.
Sample Preparation
Primary HCC tissues and normal tissues 5 cm distant from
the tumor edge were collected from each included patient
during liver resection and placed in a liquid nitrogen pre-
freezing RNase-free vial for 5 mins, then stored at −78°C
prior to RNA extraction. Tissue samples were subjected to
RNA extraction using Trizol reagent (Invitrogen, MA,
USA). The purity and concentration of RNA were deter-
mined from OD260/280 readings using a NanoDrop ND-
1000 (Invitrogen), and the integrity was evaluated using
standard denaturing agarose gel electrophoresis. RNA
extracts with a volume exceeding 8 μg underwent further
analysis.
Quantitative Real-Time PCR Reaction
To quantify the expression of CXCL14, quantitative real-
time PCR (qPCR) was performed using a CFX96 real-time
PCR detection system (Bio-Rad, CA, USA). The following
primer sequences were used for real-time RT-PCR analysis:
(CXCL14): F-5′-CTGCGAGGAGAAGATGGTTA-′3, R-5′-
CTTTGCACAAGTCTCCCAAC-′3.
PCR was performed in a final volume of 20 μL consist-
ing of 10 μL of 2 × SYBR qPCRMix, 1 μL of each primer, 2
μL cDNA, and 4 μL ddH2O. The real-time PCR conditions
were as follows: 1 cycle of 1 min at 94°C, followed by 40
cycles of 30 s at 94°C for denaturation, 15 s at 57°C for
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annealing, and 15 s at 72°C for extension, followed by 10
mins for the final extension. All samples were run in tripli-
cate. qPCR Human Reference cDNA (Takara Bio, Dalian,
China) was used as an endogenous reference gene. CXCL14
mRNA expression was normalized to the expression of
human reference cDNA. The 2−ΔΔCT method was used to
evaluate the relative change of CXCL14 expression in HCC
tissues when compared with normal adjacent tissues.
Patients with Chronic HBV Infection and
HBV-Free Controls
Overall, 212 patients with chronic HBV infection were
recruited from Zhongshan Hospital, Xiamen University
between November 2015 to December 2017. Chronic
HBV infection was confirmed by a commercial ELISA
kit and results were quantified by real-time fluorescence
quantitative PCR. To rule out confounding effects caused
by previous anti-viral treatment so that we could study
CXCL14 polymorphisms associated with chronic HBV
patients in their natural state, only treatment-naïve patients
were recruited in this study. Patients were included if they
were aged between 20 and 79 years, had HBV DNA levels
≥107 copies/mL, and had no prior history of anti-viral
treatment. The exclusion criteria were as follows: co-
infection with HCV/human immunodeficiency virus
(HIV), prior receipt of anti-viral treatment, and refusal to
participate. Eligible patients were further assigned into two
groups based on their hepatitis activity scores obtained
using the METAVIR score. Subjects with activity scores
of A0-A1 were categorized as having mild hepatitis, while
subjects with activity scores of A2-A3 were categorized as
having moderate-to-severe chronic hepatitis. Another 180
controls in this study who did not HBV, HCV, or HIV
infections were recruited by medical professionals at the
same study site. The present study was officially approved
by the Ethic Committee of Zhongshan Hospital Xiamen
University through a secret ballot and was in agreement
with the Helsinki declaration. All study subjects signed
a written informed consent form before enrollment.
Data Collection
On the date of entry, each subject was interviewed face-to-
face by an extensively trained investigator, and the following
information was collected including gender, age, weight,
height, marital status, smoking status, alcohol consumption,
and family history of hepatitis. Information on HBV infec-
tion (date of HBsAg detection, HBsAg, anti-HBs, HBeAg,
anti-HBe, and anti-HBc status, HBV genotype, HBV titer),
and the results of liver function parameters were recorded in
a database by reviewing medical records with the permission
of the subjects. The precise definitions of smoking and alco-
hol consumption were as follows: individuals who smoked at
least one cigarette per day for over one year were defined as
smokers, and those who consumed one or more alcoholic
drink per week for over 6months were categorized as alcohol
drinkers. Fibrosis stage, hepatitis activity, and inflammation
grade were established using the METAVIR system by liver
biopsy in all included subjects with chronic HBV infection.
Genotyping Assay for CXCL14
Polymorphisms
We collected a venous blood sample from each enrolled
subject. Blood samples were centrifuged at 3600 ×g for 10
mins to separate the serum and blood cells and then stored at
−78°C prior to DNA extraction. Human genome DNA was
extracted from blood cells using the Magna Pure LC 2.0
system (Roche Applied Science, Mannheim, Germany).
CXCL14 polymorphisms including rs2237061, rs2237062,
and rs2547 were genotyped by matrix-assisted laser deso-
rption/ionization time of flight mass spectrometry (MALDI-
TOF/MS). All procedures were performed according to the
manufacturer’s instructions (Sequenom, San Diego, CA,
USA). A negative water control and reference DNA were
used as quality control measures during the genotyping
assay. Approximately 5% of the samples were randomly
selected and genotyping was repeated as duplicated controls.
The genotyping call rate was 100% according to the results
from the platform.
Determination of Serum CXCL14 Levels
Serum CXCL14 levels were measured using a Human
CXCL14/BRAK DuoSet ELISA kit (R&D Systems, MN,
USA), and the lower detection limit for this kit was 62.5
pg/mL. All procedures were conducted in accordance with
the manufacturer’s instructions. After the experiment, the
results were calculated using a microplate reader set to 450
nm with a standard curve.
Statistical Analysis
The relative change of CXCL14 in tissues was compared
by Student’s t-test directly on the –ΔΔCT value. The
association between CXCL14 polymorphisms and chronic
HBV progression was evaluated by logistic regression.
Comparisons of serum CXCL14 levels between three
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groups were compared by one-way ANOVA. All statistical
analyses were conducted with SPSS software version 25
(SPSS, Inc., IL, USA).
Results
CXCL14 mRNA Expression Levels
Determined by qRT-PCR
We included 20 HBV-related male HCC cases, and HCC
tissues and adjacent tissues were collected during hepa-
tectomy. The median age among HCC cases was 46.00
years, and the mean tumor size and standard deviation
were 6.36 cm and 1.91 cm, respectively. After RNA
extraction from tissues, we used agarose gel electrophor-
esis to inspect the sample RNA’s integrity. Subsequently,
the sample RNA was subjected to qRT-PCR as described
above. CXCL14 in HCC tissues was significantly reduced
at a ratio of 0.33 compared with adjacent tissues.
Demographic Characteristics of Patients
with Chronic HBV Infection and
HBV-Free Controls
As shown in Table 1, the present study included 212
patients (including 151 mild hepatitis patients and 61
moderate-to-severe hepatitis patients) with chronic HBV
infection and 180 HBV-free controls. The mean age of
patients with mild hepatitis was 30.70±7.09 years, 31.25
±7.78 years in the moderate-to-severe hepatitis patients,
and 29.50±6.52 years in the HBV-free controls, and the
proportion of males was 66.2%, 67.2% and 66.7%,
respectively. The statistical analysis found no significant
difference in BMI, marital status, smoking status, alcohol
consumption and family history of hepatitis B between
the three groups, indicating they had comparable demo-
graphic characteristics. Regarding the HBV genotype,
81.1% of patients with chronic HBV infection were gen-
otype B, and the rest were genotype C (18.9%), consis-
tent with the genotype distribution data of Southern
China.
CXCL14 Polymorphisms and Disease
Progression of Chronic HBV Infection
In accordance with the METAVIR score system, we categor-
ized 212 patients with chronic HBV infection into mild
hepatitis (Group 1, n=151) and moderate-to-severe hepatitis
(Group 2, n=61). Based on the results of MALDI-TOF/MS,
we obtained the genotypes of rs2237061, rs2237062, and
rs2547 for all study participants. The genotype distribution
in each CXCL14 polymorphism was calculated and com-
pared between the three groups to determine whether they
were differentially distributed in patients with mild hepatitis,
moderate-to-severe hepatitis patients and HBV-free controls.
In addition, the association between the above-mentioned
CXCL14 polymorphisms and chronic HBV progression
was investigated by univariate logistic regression (Table 2).
We found that the genotype distribution of rs2237062 was
significantly different between group 1 and group 2, as well
as between group 2 and group 3. Similarly, an identical trend
was also observed in rs2547whenwe compared the genotype
distribution between the three groups. These data suggested
that the genotype CC carriers of rs2237062 had a 3.87-fold
(95%CI: 1.56–9.61) risk of developing tomoderate or severe
hepatitis compared with the wild type GG carriers. An
Table 1 Demographic Characteristics of Patients with Chronic
HBV Infection and HBV-Free Controls
Variables Mild
Hepatitis
(n=151)
Group 1
Moderate
to Severe
Hepatitis
(n=61)
Group 2
HBV-Free
Controls
(n=180)
Group 3
P value
Gender
Male 100 (66.2) 41 (67.2) 120 (66.7)
Female 51 (33.8) 20 (32.8) 60 (33.3) 0.990
Age 30.70±7.09 31.25±7.87 29.50±6.52 0.239
BMI 21.39±2.94 21.45±3.41 21.10±3.30 0.160
Marital Status
Single 40 (26.5) 19 (31.1) 62 (34.4)
Married 108 (71.5) 42 (68.9) 117 (65.0)
Divorced 3 (2.0) 0 (0.0) 1 (0.6) 0.332
Smoking Status
Smokers 17 (11.3) 13 (21.3) 28 (15.6)
Never-smokers 134 (88.7) 48 (78.7) 152 (84.4) 0.162
Alcohol
Consumption
No 20 (13.2) 14 (23.0) 39 (21.7)
Yes 131 (86.8) 47 (77.0) 141 (78.3) 0.094
Family History of
Hepatitis B
No 102 (67.5) 40 (65.6) 125 (69.4)
Yes 49 (32.5) 21 (34.4) 55 (30.6) 0.839
HBV Genotype
Genotype B 123 (81.5) 49 (80.3) –
Genotype C 28 (18.5) 12 (19.7) – 0.280
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elevated risk of chronic HBV progression was also found in
genotype AA carriers with rs2547, with anOR of 16.17 (95%
CI: 1.90–138.00). However, we did not detect any difference
in the genotype distribution of rs2237061 or its ORs calcu-
lated by univariate logistic regression. An analysis of alleles
in three CXCL14 polymorphisms was also conducted.
Similarly, we observed an elevated risk for HBV progression
in rs2237062 and rs2547 but not rs2237061.
Comparison of Liver Function Parameters
Based on CXCL14 Polymorphisms
Univariate logistic regression indicated that the polymorphism
on rs2237062 and rs2547, but not rs2237061, was positively
correlated with chronic HBV progression among patients with
chronic HBV infection. Therefore, we conducted a Student’s
t-test to compare the liver function parameters based on the
genotypes of rs2237062 and rs2547 to determine whether the
CXCL14 polymorphisms affected liver function parameters.
As shown in Table 3 and Figure 1, carriers of the GC+CC
genotype in rs2237062 demonstrated a significantly elevated
level of TBIL (29.79±4.06 vs 18.14±6.18), DBIL (9.92±4.91
vs 4.13±3.96) and IBIL (19.92±17.23 vs 15.72±10.19). No
significant differences were found among the other liver func-
tion parameters between the different genotypes of rs2237062.
Surprisingly, we also observed significant increases in ALT,
AST, and HA among carriers of the GA+AA genotype in
rs2547 when compared with GG wildtype carriers. However,
there were no differences in bilirubin between the different
genotypes of rs2547.
Comparison of Serum CXCL14 Levels
Between Groups and Genotypes
We conducted one-way ANOVA to compare CXCL14 levels
between patients withmild hepatitis, moderate-to-severe hepa-
titis and HBV-free controls. As shown in Table 4 and
Figure 2A, the CXCL14 level was 11.14±1.22 ng/mL in HBV-
free controls, while a significant reductionwas detected inmild
hepatitis patients (8.10±1.03 ng/mL) and moderate-to-severe
hepatitis patients (5.23±1.21 ng/mL) (P<0.05). To further
investigate the association between CXCL14 polymorphisms
and CXCL14 serum level, we compared the CXCL14 level
between patients with chronic HBV infection by genotype. As
shown in Table 5 and Figure 2B, there was no significant
difference in CXCL14 level between rs2237062 genotypes;
however, in contrast, a significant reduction was observed in
carriers of the GA+AA genotype (7.55±1.53 vs 7.06±1.79) in
rs2547 when compared with wild type carriers.
Table 2 The Genotype Distribution of CXCL14 Polymorphisms and Its Association with Chronic HBV Progression
Genotype Group 1 Group 2 Group 3 P value OR (95% CI)a
rs2237061
CC 110 (72.8) 43 (70.5) 132 (73.3) 0.129a 1.00 (Ref)
CT 33 (21.9) 10 (16.4) 39 (21.7) 0.991b 0.78 (0.35–1.71)
TT 8 (5.3) 8 (13.1) 9 (5.0) 0.081c 2.56 (0.90–7.25)
C 253 (83.8) 96 (78.7) 303 (84.2) 0.214 a 1.00 (Ref)
T 49 (16.2) 26 (21.3) 57 (15.8) 0.891 b 1.40 (0.82–2.38)
0.166 c
rs2237062
GG 76 (50.3) 25 (41.0) 97 (53.9) 0.006a* 1.00 (Ref)
GC 64 (42.4) 22 (36.1) 79 (43.9) 0.087b 1.05 (0.54–2.03)
CC 11 (7.3) 14 (23.0) 4 (2.2) <0.001c* 3.87 (1.56–9.61)*
G 216 (71.5) 72 (59.0) 273 (75.8) 0.012 a 1.00 (Ref)
C 86 (28.5) 50 (41.0) 87 (24.2) 0.209 b 1.74 (1.13–2.71)
<0.001 c
rs2547
GG 124 (82.1) 46 (75.4) 153 (85.0) 0.004a* 1.00 (Ref)
GA 26 (17.2) 9 (14.8) 26 (14.4) 0.773b 0.93 (0.41–2.14)
AA 1 (0.7) 6 (9.8) 1 (0.56) 0.001c* 16.17 (1.90–138.00)*
G 274 (90.7) 101 (82.8) 332 (92.2) 0.021 a 1.00 (Ref)
A 28 (9.3) 21 (17.2) 28 (7.8) 0.492b 2.04 (1.11–3.75)
0.003c
Notes: aGroup 1 vs Group 2. bGroup 1 vs Group 3. cGroup 2 vs Group 3. *P<0.05
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Discussion
The present study confirmed that reduced CXCL14 mRNA
expression in HCC tissues when compared with adjacent tis-
sues. Furthermore, two polymorphisms, but not rs2237061, in
CXCL14 were associated with more advanced progression of
chronic HBV infection and compromised liver function. We
also compared the serum CXCL14 level in patients with
chronic HBV infection and HBV-free controls and found that
the CXCL14 level was significantly higher in HBV-free con-
trols, and significantly reduced when comparing patients with
mild hepatitis and moderate-to-severe hepatitis patients. In
addition, among patients with chronic HBV infection, carriers
of rs2547 mutant had a lower CXCL14 level when compared
with wild type carriers.
Generally, CXCL14 has been acknowledged to be
a tumor suppressor in certain types of cancer, on the
basis of its low expression in carcinoma tissues and abun-
dant expression in normal tissues.10 Several anticancer
mechanisms of CXCL14 have been proposed, for exam-
ple, CXCL14 is a chemoattractant for monocytes, B cells,
dendritic cells, and NK cells. A transwell chemotaxis
assay showed that CXCL14 is involved with the traffick-
ing of NK cells to sites of malignancy; therefore, the
suppression of CXCL14 might prevent NK immune sur-
veillance, consequently leading to the promotion of
oncogenesis.12 Our results obtained from comparisons of
CXCL14 mRNA expression between HCC tissues and
Table 3 Comparison on Liver Function Parameters Among Patients with Chronic HBV Infection by CXCL14 Polymorphisms
Liver Function
Parameters
rs2237062 GG
Genotype
GC+CC
Genotype
P value rs2547 GG
Genotype
GA+AA
Genotype
P value
TBIL (umol/L) 18.14±6.18 29.79±4.06 0.003* 24.61±7.02 25.33±4.84 0.901
DBIL (umol/L) 4.13±3.96 9.92±4.91 0.013* 7.42±8.68 7.38±5.26 0.991
IBIL (umol/L) 15.72±10.19 19.92±17.23 0.028* 18.13±14.85 17.95±14.27 0.947
AST (U/L) 277.57±74.91 304.66±56.24 0.530 251.27±52.12 489.78±57.56 0.004*
ALT (U/L) 146.78±32.42 174.93±26.82 0.274 127.53±30.20 329.16±20.75 0.001*
TP (g/L) 73.37±8.28 74.37±4.55 0.265 74.28±4.50 72.30±11.91 0.089
GLOB (g/L) 41.34±5.33 42.48±3.48 0.077 42.18±3.54 41.03±7.22 0.147
ALB (g/L) 32.43±4.44 31.89±3.84 0.351 32.10±4.01 32.24±4.64 0.852
TF (g/L) 226.42±31.25 231.77±32.92 0.230 228.07±32.10 235.95±32.57 0.178
CP (g/L) 24.77±3.64 23.94±4.43 0.138 24.07±3.84 25.36±5.15 0.086
HA (ug/L) 98.03±8.07 117.34±9.78 0.124 98.64±7.50 157.78±7.87 0.023*
Note: * P<0.05.
Abbreviations: TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; ALT, alanine aminotransferase; AST, aspartate transaminase; TP, total protein; GLOB,
globulin; ALB, albumin; TF, transferrin; CP, ceruloplasmin; HA, Hyaluronan.
Figure 1 Comparison on liver function parameters by rs2237062 (A) and rs2547 (B)
genotypes. (A) DBIL, IBIL and TBIL are significantly higher in GC+CC genotype
carriers of rs2237062; (B) ALT, ASTand HA are elevated in GA+AA genotype carriers
of rs2547.
Table 4 One-Way ANOVA of CXCL14 Level Between Three
Groups
Group CXCL14 Level (ng/mL) F P value
Group 1 8.10±1.03 <0.001a*
Group 2 5.23±1.21 <0.001b*
Group 3 11.14±1.22 683.773 <0.001c*
Notes: aGroup 1 vs Group 2. bGroup 1 vs Group 3. cGroup 2 vs Group 3. *P<0.05
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normal tissues by qRT-PCR indicated that CXCL14 might
have a tumor-suppressing effect, because its expression
was 0.33-fold in HCC tissues compared with adjacent
tissues.
We also investigated the impact of an intron poly-
morphism rs2237062 and a protein-coding polymorphism
rs2547 on the progression of chronic HBV infection. We
found that the CC genotype was more frequently observed
in cases with a more advanced progression of HBV infec-
tion, and it was also correlated with elevated serum bilir-
ubin. To date, only one publication has reported the
association between CXCL14 polymorphisms and HBV
progression; however, it failed to detect a significant dif-
ference in rs2237062 genotype distribution between
patients with HCC, patients with chronic infection, and
HBV-free controls.13 However, this previous publication
did suggest that the CC genotype was more frequently
observed in HCC patients with advanced TNM stages.
Although our results of genotype distribution were not
consistent with the report published by Gu et al,14 we
both observed the involvement of CXCL14 in the devel-
opment of HCC.
Another major finding was that the AA genotype of
rs2547 was more frequent in HBV patients of advanced
stage, and that mild hepatitis patients had a similar genotype
distribution when compared with HBV-free controls. After
we applied a dominant model to compare liver function
parameters, we found that mutant genotypes, combining
GA and AA genotypes, had increased levels of ALT, AST,
and HA, which are important biomarkers for evaluating liver
fibrosis, which is an important pathological step before car-
cinogenesis. The serum level of HA has generally been
acknowledged to be a useful biomarker for diagnosing liver
fibrosis with a sensitivity of 82.4% and a specificity of
78.2%.15 Based on the results obtained above, we assumed
that rs2547 had a critical role in the progression of HBV
infection, considering all elevated liver function parameters
were of clinical significance. Currently, no known empirical
research has focused on exploring relationships between
rs2547 and HBV infection. One previous study found that
rs2547 was associated with susceptibility to developing
aggressive prostate cancer using a microarray technique.16
According to the statistical analysis, this supports the idea
that the rs2547 polymorphism is correlated with a more
severe liver impairment and fibrosis, and that AA genotype
carriers have a 16.17-fold risk of progressing to the advanced
stage of hepatitis. However, despite the large OR we
observed in univariate analysis, the data must be interpreted
with caution because of the rarity of the AA genotype in the
included study participants. Because of the difference in
frequency of the AA genotype between mild hepatitis
(0.7%) and moderate-to-severe hepatitis (9.8%), the risk
can be large in terms of mathematics. Therefore, validation
of the association between rs2547 and HBV progression in
a larger population is required.
In addition, the present study evaluated the serum
CXCL14 level in patients with HBV infection and HBV-
free controls. The results of one-way ANOVA showed
a linear trend, where CXCL14 was highest in HBV-free
Figure 2 Comparison on serum CXCL14 level by groups (A) and rs2237062 and
rs2547 genotypes (B). (A) CXCL14 protein level is higher in HBV-free controls, and
it decreases in patients with moderate and severe hepatitis; (B) CXCL14 protein
level is significantly lower in carriers of rs2547 GA+AA genotype.
Table 5 Comparison on CXCL14 Level Between Genotypes
Among Patients with Chronic HBV Infection
Genotype CXCL14 Level
(ng/mL)
t P value
rs2237062 GG genotype 7.37±1.60
GC+CC genotype 7.25±1.71 0.404 0.687
rs2547 GG genotype 7.55±1.53
GA+AA genotype 7.06±1.79 2.126 0.035*
Note: *P<0.05.
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controls, lower in patients with mild hepatitis, and lowest
in patients with moderate-to-severe hepatitis. This indi-
cated that CXCL14 was inversely correlated with HBV
progression. A comparison was also made between the
genotypes of rs2237062 and rs2547 among patients with
HBV infection; however, there was no significant differ-
ence between rs2237062 genotypes, although the wild type
GG carriers of rs2547 had a significantly higher level of
CXCL14 when compared with the GA+AA genotype.
Therefore, the gene-coding polymorphism, rs2547, might
impact the serum CXCL14 level. The polymorphism on
rs2547 introduced a stop-gain in the coding sequence to
produce an incomplete protein. Thus, it can be assumed
that the presence of the rs2547 polymorphism would lead
to the reduction of the serum level of CXCL14 and would
result in a more severe liver injury.
Conclusion
In this study, we determined an association between
CXCL14 polymorphisms and HBV progression by logistic
regression. In addition, the serum level of CXCL14
between different genotypes was compared. The current
data indicated that the serum CXCL14 level was reduced
in patients with chronic HBV infection when compared
with healthy controls. Furthermore, CXCL14 polymorph-
isms were associated with degenerated liver function,
especially rs2547, which was also associated with elevated
HA level, an important indicator of liver cirrhosis. These
findings provide important insights into the role of
CXCL14 in HBV infection. However, these results should
be considered with caution because of the small number of
study participants. Therefore, further investigation should
be undertaken to investigate how CXCL14 affects liver
function and carcinogenesis.
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